Pfizer bags approval for RA drug Xeljanz

27th March 2017 Uncategorised 0

Some patients with moderate to severe forms of rheumatoid arthritis could get access to a new treatment option in Europe following the approval of Pfizer’s oral Janus kinase (JAK) inhibitor Xeljanz.

More: Pfizer bags approval for RA drug Xeljanz
Source: News